Abstract
Efficacy and Safety of Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Extended Follow-up from the GHSG Phase II Nivahl Trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have